STOCK TITAN

Insulet appoints Michael R. Minogue to its board

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Insulet Corporation (PODD) appointed Michael R. Minogue to its board, effective November 20, 2026. He will again serve as a Class I director, with a term expiring at the 2029 Annual Meeting of Stockholders. Minogue previously served on the board from August 2017 until September 2026, when he resigned to focus on his candidacy for Governor of Massachusetts. He was chairman, president and CEO of Abiomed from 2004 until its sale in December 2022.

As a non-employee director, Minogue will receive an initial restricted-stock-unit grant with an approximately $121,700 grant-date fair value, representing the pro-rated value of the $260,000 annual equity award under Insulet’s director compensation program. He will also receive cash compensation under that program.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Initial restricted-stock-unit grant-date fair value approximately $121,700 For Michael R. Minogue as a non-employee director
Annual equity award $260,000 Annual award under the non-employee director compensation program
restricted stock units financial
"initial grant of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Michael R. Minogue join the Insulet (PODD) board?

Michael R. Minogue's appointment is effective November 20, 2026, and he will serve as a Class I director through a term expiring at the 2029 Annual Meeting of Stockholders.

What director compensation will Michael R. Minogue receive from Insulet (PODD)?

He will receive an initial restricted-stock-unit grant with an approximately $121,700 grant-date fair value, representing the pro-rated value of the $260,000 annual equity award; he will also receive cash compensation under the non-employee director compensation program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001145197FALSE00011451972026-11-192026-11-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 19, 2026
 
INSULET CORPORATION
(Exact name of registrant as specified in its charter)

Delaware001-3346204-3523891
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
100 Nagog Park
ActonMassachusetts01720
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:
(978)600-7000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐




Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value Per Share
PODDThe NASDAQ Stock Market, LLC



Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 19, 2026, the Board of Directors (the "Board") of Insulet Corporation (the "Company") appointed Michael R. Minogue to the Board, effective November 20, 2026. Mr. Minogue previously served on the Board as a Class I director from August 2017 until September 2026, when he resigned to focus on his candidacy for Governor of Massachusetts. Mr. Minogue will again serve as a Class I director, with a term expiring at the Company’s 2029 Annual Meeting of Stockholders.
Mr. Minogue is the President and CEO of Minogue Consulting, LLC and Heartwork Capital, LLC, providing services for executive teams, boards and college students through leadership development programs, speaking engagements and one-on-one mentoring and investing in companies elevating the standard of care in medicine. From 2004 until its sale in December 2022, Mr. Minogue served as Chairman of the Board, President and Chief Executive Officer of Abiomed, Inc., a global leader in healthcare technology and innovation. Prior to joining Abiomed, he spent 11 years with General Electric Healthcare, where he held numerous leadership roles and holds three patents. Mr. Minogue served as a director of the Advanced Medical Technology Association (AdvaMed), a medical device industry association, from 2007 to 2023, serving as Chairman from 2021 to 2023. In addition, he has served on the Boards of Directors of LifeCell, Bioventus and the Medical Device Innovation Consortium (MDIC) and as Chairman of the Governor’s Advisory Council on Veterans’ Services for the Commonwealth of Massachusetts. Mr. Minogue cofounded and is a director of the Mike and Renee Minogue Foundation and MedTechVets, a 501(c)(3) nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the medtech industry. Mr. Minogue served as an officer in the U.S. Army, receiving multiple distinctions, including Airborne, Ranger, Desert Storm veteran and a Bronze Star. He received a Bachelor of Science in Engineering Management from the United States Military Academy at West Point and an MBA from the University of Chicago Graduate School of Business.
There are no arrangements or understandings between Mr. Minogue and any other persons pursuant to which he was selected as a director. There are no transactions involving Mr. Minogue required to be disclosed pursuant to Item 404(a) of Regulation S-K. As non-employee directors of the Company, Mr. Minogue will receive an initial grant of restricted stock units having a grant date fair value of approximately $121,700, representing the pro-rated value of the $260,000 annual equity award under the Company’s non-employee director compensation program. He will also receive cash compensation under that program, as described in the “Non-Employee Director Compensation” section of the Company's proxy statement filed with the Securities and Exchange Commission on April 6, 2026, as may be amended by the Board from time to time.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned thereunto duly authorized.
 
INSULET CORPORATION
November 20, 2026By:/s/ John W. Kapples
Name:John W. Kapples
Title:Senior Vice President and General Counsel

Filing Exhibits & Attachments

3 documents

Keep reading